MARKER THERAPEUTICS, INC.
MRKR Healthcare Biotechnology
In the quarter to June 2026, revenue grew 2.75%, EPS grew 69.0% and free cash flow fell 97.8%, each against the same quarter a year earlier.
Follow MRKR
MARKER THERAPEUTICS, INC. (MRKR) EV/Sales
As of 16 October 2026, MARKER THERAPEUTICS, INC. (MRKR) trades at a EV/Sales of 1.9×. Over the past ten years it has ranged from −6.8× (February 2022) to 171× (July 2021); the current reading is higher than 64% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.6× | (0.79%) |
| FY2024 | 1.6× | (84.41%) |
| FY2023 | 10.2× | 193.24% |
| FY2022 | 3.5× | (75.26%) |
| FY2021 | 14.0× | (68.30%) |
| FY2020 | 44.2× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | 1.6× | — |
| Sep 2025 | −0.5× | — |
| Jun 2025 | 2.1× | 608.93% |
| Mar 2025 | 0.3× | (81.42%) |
| 17 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VAXX Vaxxinity, Inc. compare | −94.2× |
| TCRX TScan Therapeutics, Inc. compare | −5.3× |
| AKTX Akari Therapeutics PLC compare | n/m |
| NCEL NewcelX Ltd. compare | n/m |
| PBM Psyence Biomedical Ltd. compare | n/m |
| ADAPY Adaptimmune Therapeutics PLC compare | 0.1× |
| MRKR MARKER THERAPEUTICS, INC. | 1.9× |
| DARE Dare Bioscience, Inc. compare | 4.7× |
| GTBP GT Biopharma, Inc. compare | 543× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)